DOI: 10.12890/2023_003654

Dalbavancin for Successful Treatment of Infective Endocarditis Caused by Enterococcus faecalis

Authors

  • Francisco Javier Teigell Muñoz Department of Internal Medicine, Infanta Cristina University Hospital, Madrid, Spain
  • María Mateos-González Department of Internal Medicine, Infanta Cristina University Hospital, Madrid, Spain
  • Elsa Bernal-Hertfelder Department of Medical Oncology, Infanta Cristina University Hospital, Madrid, Spain
  • Ana Sánchez de Torre Department of Medical Oncology, Infanta Cristina University Hospital, Madrid, Spain
  • María García-Ferrón Department of Medical Oncology, Infanta Cristina University Hospital, Madrid, Spain
  • Carmen de Cáceres Velasco Department of Hospital Pharmacy, Infanta Cristina University Hospital, Madrid, Spain
  • Coralia Bueno Muiño Department of Medical Oncology, Infanta Cristina University Hospital, Madrid, Spain

javier.teigell@gmail.com

Keywords

Infective endocarditis, dalbavancin, Enterococcus, outpatient parenteral antimicrobial therapy, OPAT

Abstract

Infective endocarditis is a relatively uncommon infection that requires a high index of suspicion, which can sometimes delay its diagnosis. It requires several weeks of intravenous antibiotics, which traditionally requires long hospital stays. Dalbavancin is a novel antibiotic with high activity against several Gram-positive pathogens. Its weekly administration allows the outpatient management of complicated infections requiring parenteral treatment, but only a few cases of Enterococcus faecalis endocarditis treated with dalbavancin have been reported in the literature. We here report a case of successful treatment with dalbavancin of an infectious endocarditis caused by E. faecalis.

View the entire article

Downloads

References

  1. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015;36:3075.
  2. Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, et al. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna. Clin Infect Dis 2018;67(5):795–798.
  3. Hidalgo-Tenorio C, Vinuesa D, Plata A, Martin Dávila P, Iftimie S, Sequera S, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob 2019;18(1):30.
  4. Herrera-Hidalgo L, de Alarcón A, López-Cortes LE, Luque-Márquez R, López-Cortes LF, Gutiérrez-Valencia A, et al. Enterococcus faecalis endocarditis and outpatient treatment: a systematic review of current alternatives. Antibiotics (Basel) 2020;9(10):657.
  5. Raad I, Darouiche R, Vazquez J, Lentnek A, Hachem R, Hanna H, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005;40(3):374–380.
  6. Ajaka L, Heil E, Schmalzle S. Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care. Antibiotics (Basel) 2020;9(10):700.

Published

2023-02-03

Issue

Vol. 10 No. 1 (2023)

Categories

How to Cite

1.
Teigell Muñoz FJ, Mateos-González M, Bernal-Hertfelder E, Sánchez de Torre A, García-Ferrón M, de Cáceres Velasco C, et al. Dalbavancin for Successful Treatment of Infective Endocarditis Caused by Enterococcus faecalis . EJCRIM [Internet]. 2023 Feb. 3 [cited 2026 Nov. 3];10(1). Available from: https://ejcrim.com/index.php/ejcrim/article/view/3654